K-Ras(G12C) inhibitor 6 is primarily used in cancer research and treatment, specifically targeting cancers driven by the K-Ras(G12C) mutation. This mutation is commonly found in various cancers, including lung, colorectal, and pancreatic cancers. The inhibitor works by selectively binding to the mutated K-Ras protein, blocking its activity and preventing the signaling pathways that promote tumor growth and survival. Its application is significant in developing targeted therapies, offering a more precise approach compared to traditional chemotherapy. Researchers use this compound to study the mechanisms of K-Ras-driven cancers and to evaluate its efficacy in preclinical and clinical trials, potentially leading to improved treatment options for patients with these mutations.